View Detailed Profile
Bill Ackman defends Valeant

Bill Ackman defends Valeant

FBN's Charlie Gasparino on Pershing Square's

Bill Ackman Sells Valeant Stake After $2.8 Billion Loss

Bill Ackman Sells Valeant Stake After $2.8 Billion Loss

Mar.14 --

Bill Ackman: Betting big on tech cash cows after Pershing Square underperformance

Bill Ackman: Betting big on tech cash cows after Pershing Square underperformance

AJ Bell's Head of Markets, Dan Coatsworth, sits down with

Bill Ackman: There's a Lot of Misinformation on Drug Pricing

Bill Ackman: There's a Lot of Misinformation on Drug Pricing

Oct. 6 -- Activist investor

Ackman: Plan to Discuss Drug Prices With Valeant Board

Ackman: Plan to Discuss Drug Prices With Valeant Board

April 27 --

Bill Ackman defends $10K donation to ICE agent

Bill Ackman defends $10K donation to ICE agent

Billionaire

Bill Ackman - Talks about Valeant

Bill Ackman - Talks about Valeant

Bill Ackman

Ackman: Allergan tried to 'malign' Valeant with false statements

Ackman: Allergan tried to 'malign' Valeant with false statements

Activist investor

Bill Ackman goes corporate raider route backing Valeant in Allergan bid

Bill Ackman goes corporate raider route backing Valeant in Allergan bid

With

Billionaire investor Bill Ackman: Kennedy made me think about risk vs. reward with vaccines

Billionaire investor Bill Ackman: Kennedy made me think about risk vs. reward with vaccines

Pershing Square Capital Management CEO

Bill Ackman on Valeant: Mistakes Were Made

Bill Ackman on Valeant: Mistakes Were Made

Bill Ackman

Ackman's Pershing Square Capital reportedly losing investors at rapid pace

Ackman's Pershing Square Capital reportedly losing investors at rapid pace

FBN's Connell McShane on concerns about the future of

Nightly Business Report: Behind the Ackman Allergan deal

Nightly Business Report: Behind the Ackman Allergan deal

Dominic Chu explains the artful way in which activist investor